Table 1 General characteristics of the included trials
From: An evidence mapping and analysis of registered COVID-19 clinical trials in China
Number | Percentage | |
|---|---|---|
Study type | ||
Interventional | 159 | 72.3 |
Observational | 61 | 27.7 |
Study initiator | ||
Hospital | 176 | 80.0 |
Industry | 20 | 9.1 |
University | 19 | 8.6 |
Other | 5 | 2.3 |
Recruitment status | ||
Not yet recruiting | 97 | 44.0 |
Recruiting | 122 | 55.5 |
Completed | 1 | 0.5 |
Length of study time | ||
L ≤ 3m | 77 | 35.0 |
3 < L ≤ 6m | 44 | 20.0 |
6 < L ≤ 12m | 67 | 30.5 |
12 < L ≤ 24m | 23 | 10.5 |
L > 24 | 2 | 0.9 |
NP | 7 | 3.1 |
Age group of the recruited or intended population | ||
0–1 | 1 | 0.5 |
0–18 | 1 | 0.5 |
3 years and older | 1 | 0.5 |
12 years and older | 1 | 0.5 |
14 years and older | 5 | 2.3 |
15 years and older | 2 | 0.9 |
16 years and older | 4 | 1.8 |
18 years and older | 132 | 60.0 |
22 years and older | 1 | 0.5 |
30 years and older | 1 | 0.5 |
60 years and older | 1 | 0.5 |
All | 15 | 6.8 |
NP | 55 | 25.0 |
Locations | ||
China | 197 | 89.5 |
NP | 23 | 10.5 |
Collaborators | ||
Chinese collaborators | 71 | 32.3 |
International collaborators | 4 | 1.8 |
NP | 145 | 65.9 |
Data monitoring committee | ||
Has data monitoring committee | 101 | 45.9 |
Not have data monitoring committee | 22 | 10.0 |
Not yet determined | 47 | 21.4 |
NP | 50 | 22.7 |
Study start date (year, month) | ||
2020, January | 34 | 15.5 |
2020, February | 180 | 81.8 |
2020, March | 6 | 2.7 |
Study sponsor | ||
Government | 65 | 29.5 |
Government and industry | 2 | 0.9 |
Government and hospital | 1 | 0.5 |
Hospital | 44 | 20.0 |
Hospital and industry | 2 | 0.9 |
Hospital and university | 1 | 0.5 |
Industry | 13 | 5.9 |
University | 14 | 6.4 |
NP | 78 | 35.5 |
Ethical approval | ||
Obtained | 142 | 64.5 |
Non-obtained | 39 | 17.7 |
NP | 39 | 17.7 |
Number of research centers | ||
Single center | 104 | 47.3 |
Multicenter | 79 | 35.9 |
NP | 37 | 16.8 |